These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17296996)

  • 1. Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy.
    Usiskin SI; Bainbridge A; Miller RF; Jäger HR
    AJNR Am J Neuroradiol; 2007 Feb; 28(2):285-6. PubMed ID: 17296996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy treated with highly active anti-retroviral therapy].
    Shimizu Y; Ota K; Takeuchi M; Iwata M; Yogo Y
    Rinsho Shinkeigaku; 2000 Aug; 40(8):821-6. PubMed ID: 11218704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
    Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
    HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection.
    Inui K; Miyagawa H; Sashihara J; Miyoshi H; Tanaka-Taya K; Nishigaki T; Teraoka S; Mano T; Ono J; Okada S
    Brain Dev; 1999 Sep; 21(6):416-9. PubMed ID: 10487477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy.
    Thurnher MM; Post MJ; Rieger A; Kleibl-Popov C; Loewe C; Schindler E
    AJNR Am J Neuroradiol; 2001 May; 22(5):977-84. PubMed ID: 11337345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
    Polk C; Chan-Tack KM; Kopack AM; Amoroso A
    AIDS Patient Care STDS; 2007 Feb; 21(2):75-7. PubMed ID: 17328655
    [No Abstract]   [Full Text] [Related]  

  • 9. Progressive multifocal leukoencephalopathy in an HIV patient receiving successful long-term HAART.
    Mascarello M; Lanzafame M; Lattuada E; Concia E; Ferrari S
    J Neurovirol; 2011 Apr; 17(2):196-9. PubMed ID: 21445699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?
    Di Giambenedetto S; Vago G; Pompucci A; Scoppettuolo G; Cingolani A; Marzocchetti A; Tumbarello M; Cauda R; De Luca A
    Neurology; 2004 Dec; 63(12):2452-3. PubMed ID: 15623736
    [No Abstract]   [Full Text] [Related]  

  • 11. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy.
    Lanzafame M; Ferrari S; Lattuada E; Corsini F; Deganello R; Vento S; Concia E
    Infez Med; 2009 Mar; 17(1):35-7. PubMed ID: 19359824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir].
    Torres Isidro MV; García Benayas T; del Val Gómez Martínez M; González Gallardo F; Gambí Pisonero N; Castilla Miguel S; González-Lahoz J; Gallego Sanz D
    Rev Esp Med Nucl; 2006; 25(2):103-6. PubMed ID: 16759616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The inefficacy of zidovudine (AZT) in progressive multifocal leukoencephalopathy (PML) associated with the acquired immunodeficiency syndrome (AIDS)].
    Garrote FJ; Molina JA; Lacambra C; Mollejo M; Madero S; del Ser T
    Rev Clin Esp; 1990 Nov; 187(8):404-7. PubMed ID: 2091134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.
    Cinque P; Pierotti C; Viganò MG; Bestetti A; Fausti C; Bertelli D; Lazzarin A
    J Neurovirol; 2001 Aug; 7(4):358-63. PubMed ID: 11517417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroradiological study of progressive multifocal leukoencephalopathy associated with acquired immunodeficiency syndrome by MR imaging including diffusion-weighted imaging].
    Uchibori A; Kobayashi Y; Chiba A; Tsuchiya K; Zheng HY; Yogo Y; Sakuta M
    Rinsho Shinkeigaku; 2004 Aug; 44(8):531-6. PubMed ID: 15471089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy.
    Albrecht H; Hoffmann C; Degen O; Stoehr A; Plettenberg A; Mertenskötter T; Eggers C; Stellbrink HJ
    AIDS; 1998 Jul; 12(10):1149-54. PubMed ID: 9677163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to highly active antiretroviral therapy: early experience.
    Buckle C; Castillo M
    AJNR Am J Neuroradiol; 2010 Jun; 31(6):1031-5. PubMed ID: 20360338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M
    AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459
    [No Abstract]   [Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.
    Tantisiriwat W; Tebas P; Clifford DB; Powderly WG; Fichtenbaum CJ
    Clin Infect Dis; 1999 May; 28(5):1152-4. PubMed ID: 10452651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.